Casdin Capital LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Casdin Capital LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 165,323 shares of the company’s stock, valued at approximately $1,118,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after acquiring an additional 244,278 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Recursion Pharmaceuticals by 6.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock worth $7,751,000 after purchasing an additional 67,464 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares during the last quarter. Green Alpha Advisors LLC increased its holdings in Recursion Pharmaceuticals by 3.6% during the fourth quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock worth $454,000 after buying an additional 2,346 shares during the last quarter. Finally, DBK Financial Counsel LLC bought a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $101,000. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on RXRX shares. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Morgan Stanley cut their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.20.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $4.76 on Tuesday. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The stock’s 50-day simple moving average is $5.75 and its 200 day simple moving average is $6.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -3.11 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.39) earnings per share. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.